FindMyKOL
Clinical trialNCT00069030CompletedPhase 1Interventional

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment70HIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory. Only part of the virus's DNA is used in the vaccine and the vaccine itself cannot cause HIV infection or AIDS. In addition to HIV DNA, the vaccine contains interleukin-2 (IL-2) DNA fused to a portion of immunoglobulin (Ig) DNA. IL-2 is a chemical that stimulates the immune system and may improve response to the vaccine. Study hypothesis: The IL-2/Ig plasmid will be very well tolerated in humans.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Project Brave Hiv Vaccine Crs

    Baltimore, Maryland, United States

  • Brigham and Women'S Hosp. Crs

    Boston, Massachusetts, United States

  • Fenway Community Health Clinical Research Site (fchcrs)

    Boston, Massachusetts, United States

  • Hiv Prevention & Treatment Crs

    New York, New York, United States

  • Ny Blood Ctr./union Square Crs

    New York, New York, United States

  • Ny Blood Ctr./bronx Crs

    The Bronx, New York, United States

  • Miriam Hospital'S Hvtu

    Providence, Rhode Island, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

VRC-HIVDNA009-00-VP with adjuvant VRC-ADJDNA004-IL2-VP
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2003
Primary completion
—
Completion
31 Dec 2006
Last update posted
14 Oct 2021
Registered enrollment
70
Registry id
NCT00069030
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.